Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
HOTH
HOTH
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
HOTH News
Hoth Therapeutics Launches AI Drug Development Platform OpenClaw™
4d ago
PRnewswire
Hoth Therapeutics Launches AI Drug Development Platform OpenClaw™
4d ago
Newsfilter
Hoth Therapeutics Reports Positive Data for HT-001
6d ago
PRnewswire
Hoth Therapeutics Reports Positive Data for HT-001
6d ago
Newsfilter
Hoth Therapeutics Advances GDNF for Metabolic Dysfunction
Mar 10 2026
PRnewswire
Hoth Therapeutics Integrates AI for IND Preparation and Phase 1 Progression
Mar 04 2026
PRnewswire
Hoth Therapeutics Integrates AI to Support Rare Cancer Therapy Progression
Mar 04 2026
Newsfilter
Hoth Therapeutics Utilizes OpenAI API to Enhance Progress of Orphan HT-KIT Oncology Initiative
Mar 04 2026
moomoo
Hoth Therapeutics Deploys OpenAI API to Support HT-KIT Development
Mar 04 2026
Benzinga
Hoth Therapeutics Expands CLEER-001 Clinical Trial Amid Rising Patient Demand
Feb 24 2026
PRnewswire
Hoth Secures Patent to Enhance Immunology IP Portfolio
Feb 12 2026
PRnewswire
Hoth Therapeutics' GDNF Study Outperforms Semaglutide in Key Metrics
Feb 10 2026
stocktwits
Hoth Therapeutics' GDNF Therapy Shows Breakthrough Efficacy in Obesity Treatment
Feb 10 2026
PRnewswire
Hoth Therapeutics' GDNF Therapy Outperforms Semaglutide in Preclinical Study
Feb 10 2026
Newsfilter
Hoth Therapeutics Reveals GDNF Study Data for Obesity Treatment
Feb 10 2026
Benzinga
Hoth Therapeutics Reports Significant Clinical Results from HT-001 Trial in Cancer Patients
Jan 22 2026
Benzinga
Show More News
